The European Medicines Agency (EMA), in close cooperation with the United States Food and Drug Administration (FDA) recently held a two-day workshop on drug-related progressive multifocal leukoencepalopathy (PML). The aim of the meeting was to bring together experts and stakeholders in the field of PML to identify research questions that will address knowledge gaps in order to reduce the burden of the disease. Further information can be found at the link below.